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Abstract
Background: uPA/uPAR is a multifunctional system that is over expressed in many cancers and plays a critical role
in glioblastoma (GBM) invasion. Previous studies from our lab have also shown that uPA/uPAR down regulation
inhibits cancer cell invasion in SNB 19 GBM cells.
Methods: As Notch 1 is known to be over expressed and promotes invasion in glioblastoma, we therefore tested
our hypothesis of whether down regulation of uPA/uPAR, singly or in tandem, attenuates GBM invasion via Notch
1 receptor. Targeted down regulation of uPA/uPAR, either singly or simultaneously, inhibited the anchorage
independent growth of U251MG and GBM xenograft cell lines 4910 and 5310 as assessed by soft agar colony
formation assay. Expression of all four Notch receptors was confirmed in GBM tissue array analysis by
immunohistochemistry.
Results: Down regulation of uPA/uPAR, either singly or simultaneously, in U251 MG and tumor xenografts
inhibited the cleavage of the Notch receptor between the Gly 1743 and Val 1744 positions, thereby suggesting
inhibition of activated cytosolic fragment-related Notch gene transcription. Morphological analysis confirmed
inhibition of NICD when U251 MG cells were treated with puPA, puPAR or pU2. uPA/uPAR down regulation
inhibited Notch 1 mRNA in all three examined cell lines. uPA/uPAR shRNA down regulated nuclear activation of
NF-B subunits and phosphorylation of AKT/mTOR pathway in U251 MG and GBM xenografts. puPA down
regulated NICD and HES induced phosphorylation of AKT/ERK and NF-B. Down regulation of Notch 1 using siRNA
inhibited uPA activity as shown by fibrinogen zymography. It also decreased uPA expression levels as shown by
western blotting. Exogenous addition of uPA activated Notch 1 in uPAR antisense U251 MG cells and also in uPAR
antisense cells transfected with siRNA against Delta and Jagged. The Notch 1 receptor co-localized with LAMP-1, a
marker for lysosomes in uPA, uPAR and U2, down regulated U251 MG cells which probably indicates inhibition of
Notch 1 receptor trafficking in GBM cells. Notch 1 expression was significantly inhibited in puPA- and pU2-treated
pre-established intracranial tumors in mice.
Conclusions: Overall our results show that down regulation of uPA/uPAR, either singly or simultaneously, could be
an effective approach to attenuate Notch 1 receptor cleavage, signaling and endosomal trafficking in U251MG cells
and xenografts, and ultimately inhibiting GBM invasion.
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Background
In spite of the recent development of targeted therapies
(e.g., Temozolomide and avastin), glioblastoma (GBM)
still continues to be a medical challenge. Identification
of novel targets such as uPA and uPAR that are over
expressed in glioblastoma and understanding the differ-
ent signaling pathways they regulate will greatly enhance
the clinical treatment and outcome for patients affected
with glioblastoma.
The uPA/uPAR system is a multifunctional system
which is involved in several cellular processes like
migration, angiogenesis and invasion. Studies by others
and us have conclusively shown that the uPA/uPAR sys-
tem significantly correlates to tumor aggressiveness and
poor outcome. Our studies have also shown that shRNA
constructs directed against uPA/uPAR, either singly or
in combination, have a significant inhibitory effect on
the migration, invasion and angiogenesis of GBM cells
and xenografts.
Notch signaling is a highly conserved pathway playing
an important role during embryo development and
adulthood. In mammals, it consists of four receptors,
namely Notch 1, Notch 2, Notch 3 and Notch 4 [1,2].
The Notch receptor is a hetero-oligomer and a single-
pass transmembrane receptor. The transmembrane
monomer is bound through non-covalent interactions to
a fully extracellular monomer. Notch is involved in cell
proliferation, apoptosis, differentiation, survival and sta-
bilization of arterial endothelial fate, angiogenesis and
many other functions [3,4]. Notch signaling is deregu-
lated in many cancers including glioblastoma [5]. The
Notch receptor contains the extracellular peptide which
contains EGF repeats that non-covalently associate with
the transmembrane peptide and binds the Notch ligands
(e.g. Delta and Jagged). Upon ligand binding, the Notch
receptor is cleaved and sensitized by ADAM metallopro-
teases and gamma secretase. This leads to cleavage of
NICD (Notch intracellular domain) to the nucleus, and
the NICD forms a complex with CBF-1 and the tran-
scriptional co-activator MAML for transcription of
Notch genes [6]. Previous studies have shown that inhi-
bition of Notch signaling by pharmacological or genetic
means leads to cell cycle arrest and suppression of cell
growth [7-9].
We have shown that uPA and uPAR downregulation
inhibits invasion in SNB19 glioma cells by decreasing
phosphorylation of the Ras-activated FAK, p38MAPK,
JNK and ERK1/2, as well as the MEK-activated phos-
phatidylinositol 3-kinase, AKT and mTOR pathway,
indicative of a feedback signaling mechanism of the
uPAR/uPA system [10]. Moreover, studies have shown
that Notch 1 signaling is known to cross talk with ERK,
NF-B and with the PI3-K/AKT/mTOR pathway [1].
Notch has multiple roles in invasion and angiogenesis of
many human cancers but the mechanisms are not
understood [11,12]. In this study, we have shown that
down regulation of uPA and uPAR inhibits invasion of
U251 MG cells and xenograft glioma cells by inhibition
of Notch- related gene transcription, signaling mechan-
ism and targeting Notch 1 to the lysosomal pathway.
We have also shown that uPA/uPAR down regulation
inhibits Notch 1 expression in pre-established tumors in
nude mice. Overall, our results suggest that down regu-
lation of uPA/uPAR, either singly or in combination,
results in the inhibition of glioma cell invasion via inhi-
bition of Notch 1 receptor cleavage, signaling and endo-
somal trafficking of the Notch 1 receptor.
Methods
Cells and Reagents
U251 MG cells were obtained from American Type Cul-
ture Collection, (Manassas, VA), and glioma xenograft
cell lines (5310 & 4910) were kindly provided by Dr.
David James (University of California, San Francisco,
San Francisco, CA). All cell lines were cultured as
described previously [10]. Antibodies to Notch 1, 2, 3
and 4 were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA). Antibodies to cleaved Notch between
Gly 1743 and Val 1744 were obtained from Cell Signal-
ing (Beverly MA). Antibodies to extracellular domain of
Notch were obtained from Abcam (Cambridge, UK).
Antibodies to Delta and Jagged were obtained from
Santa Cruz Biotechnology, (Santa Cruz, CA). Antibodies
to RBPJ, Lamin B, alpha tubulin, pAKT, NF-B p65,
MEK, pERK, pmTOR Ser 2448, were obtained from Cell
Signaling (Beverly MA). Antibodies to uPA and uPAR
were purchased from R&D Systems (Minneapolis, MN).
Notch 1 siRNA and antibodies to GAPDH and LAMP-1
were purchased from SCBT (Santa Cruz, CA).
uPA and uPAR shRNA constructs
shRNA sequences targeting uPAR and uPA were con-
structed according to our previous publication [13].
Transfection with shRNA constructs
1.5 × 105 cells were plated in 100 mm petri dishes for
each transfection experiment. The cells were transfected
in serum-free L-15 media using 10 μg of Fugene reagent
(Roche, USA) according to the manufacturer’s instruc-
tions. The following constructs were used for transfec-
tion: puPA, puPAR, pU2 (both uPA and uPAR) and
pSV (scrambled vector). No plasmid was introduced in
the control plates. After 12 hrs of transfection, the
serum-free media was replaced with serum-containing
media and the cells were left in the incubator at 37°C
for 48 hrs. The media was then replaced with serum-
free media, and conditioned media was collected 12 hrs
later. Cells were harvested for isolation of total RNA
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and/or total cell lysates. Conditioned media was used for
fibrinogen plasminogen zymography.
Fibrinogen plasminogen zymography
We used fibrin zymography to determine the activity of
the plasminogen activators as previously described [14].
The samples were subjected to SDS-PAGE with 10%
gels that contained fibrinogen and plasminogen. Follow-
ing electrophoresis, the gels were washed twice with
2.5% (v/v) Triton X-100 for 30 min each time to remove
SDS. Finally, the gels were incubated with 0.1 M glycine
buffer (pH 7.5) at 37°C overnight, stained with amido
black, and then destained. The final gel had a uniform
background except in regions to which uPA had
migrated and cleaved its substrate.
Western blotting
U251 MG, 5310 and 4910 cells were left untreated or
transfected with puPA, puPAR or pU2. Cells were col-
lected and whole cell lysates were prepared by lysing
cells in RIPA lysis buffer containing a protease inhibitor
cocktail (Sigma, St. Louis, MO). Equal amounts of pro-
tein fractions, immunoprecipitates or lysates were
resolved by SDS-PAGE and transferred to a polyvinyli-
dene difluoride membrane. Proteins were detected with
appropriate primary antibodies followed by HRP-conju-
gated secondary antibodies. Comparable loading of pro-
teins was verified by reprobing the blots with an
antibody specific for the housekeeping gene product,
GAPDH.
Reverse transcriptase polymerase chain reaction
Total RNA was isolated from U251MG, 4910 and 5310
cells using the TRIzol reagent as per the standard proto-
col. Total RNA was treated with DNAse I (Invitrogen,
Carlsbad, CA) to remove contaminating genomic DNA.
PCR analysis was done using the one-step reverse tran-
scription-PCR kit (Invitrogen, Carlsbad, CA). Glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH) was used
as an internal control. The following primers were used:
Notch 1 Forward 5’-CAGCTTGCACAACCAGACA-
GAC-3’
Notch 1 Reverse 5’-ACGGAGTACGGCCCATGTT-3’
Notch 2 Forward AACTGTCAGACCCTGGTGAAC
Notch 2 Reverse CGACAAGTGTAGCCTCCAATC
Notch 3 Forward TGACCGTACTGGCGAGACT
Notch 3 reverse CCGCTTGGCTGCATCAG
Notch 4 Forward AGTCCAGGCCTTGCCAGAACG




The PCR conditions were as follows: 95°C for 5 min.,
followed by 30 cycles of 95°C for 1 min., and annealing
temperature set according to the AT and GC content of
the primers.
NF-B family transcription factor assay
Nuclear extracts from untreated U251 MG, 5310 and
4910 cells transfected with pSV, puPA, puPAR or pU2
were assayed for activation of NF-B transcription factor
by TransAM NF-B family activation kit (Active Motif,
Carlsbad, CA) according to the manufacturer’s
instructions.
Immunofluorescence assay
U251 MG, 4910 and 5310 cells were either transfected
with pSV, puPA, puPAR or pU2 or left untransfected.
The cells were then fixed, permeabilized, stained with
primary antibodies against Notch 1 and LAMP-1,
washed, incubated with Alexa fluor tagged secondary
antibodies, washed with PBS and mounted in an anti-
fading reagent containing DAPI. The cells were then
visualized using a confocal microscope using Olympus
Fluoview software.
uPA/uPAR quantification by ELISA
Conditioned medium from mock and pSV, puPA,
puPAR, or pU2-transfected U251 MG, 5310 and 4910
cells were subjected to ELISA for uPA and uPAR (R&D
Systems, Minneapolis, MN) according to the manufac-
turer’s instructions.
Soft colony agar assay
Anchorage independent growth was determined by
assaying colony formation in soft agar [15]. Briefly,
U251 MG, 5310 and 4910 cells which were either
untreated or transfected with pSV, puPA, puPAR or
pU2 were suspended in DMEM or RPMI containing
10% FBS and 0.33% sea plaque low-melting temp agar-
ose. 2 ml containing 2 × 104 cells were plated on a 35
mm dish over a 3 ml layer of solidified DMEM/RPMI
10% FBS and 0.6% agarose. The cells were fed by adding
200 μl of RPMI/10% FBS or with DMEM/10% FBS. The
colonies were photographed at 10x and 20x magnifica-
tion after 4 weeks.
Matrigel invasion assay
Invasion of U251MG and 4910 cells was determined by
a Matrigel invasion assay as described previously [16].
Briefly, U251MG, 4910 cells which were either left
untreated, treated with DAPT (N-[N-(3,5-Difluorophe-
nacetyl)-L-alanyl]-S-phenylglycine t-butyl ester ( NICD
inhibitor) for 1 h at 37°C or transfected with pSV,
puPA, puPAR or pU2 were detached, washed twice in
PBS, suspended in serum-free medium and seeded in
the upper chamber of a Transwell insert (8-μm pores)
coated with matrigel (1 mg ml-1) (Collaborative
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Research Inc., Boston, MA). The lower chamber was
filled with 700 μl of complete medium. After 18 hrs of
incubation period, the non-migrated cells in the upper
chamber were gently scraped away, and invaded cells
present on the lower surface of the insert were stained
with Hema-3 (Fisher Diagnostics, Middletown, VA).
Photographs of the invaded cells were taken with a light
microscope (Olympus IX-71, Minneapolis, MN).
Co-localization of Notch 1 with LAMP-1
Semi-confluent U251 MG cells grown in 8-well chamber
slides were left untreated or transfected with pSV,puPA,
puPAR and pU2. After 48 hrs, the cells were washed,
fixed with 2% paraformaldehyde, permeabilized in 0.5%
Triton X-100, and stained with primary antibodies
against Notch-1 and LAMP-1. The cells were then
washed and further incubated with appropriate second-
ary Alexa fluor antibodies, and examined under an
Olympus Fluoview microscope.
Animal experiments
U251 MG cells (2 × 106) were injected into the brains of
nude mice using a stereotactic frame. After 8-10 days
the mice were treated with pSV, puPAR, puPA and
pU2. The in vivo intracranial delivery of the vectors was
performed using Alzet mini-osmotic pumps (Direct
Corp, Cupertion, CA) at the rate of 0.25 μl/h [mock
(PBS), 150 μg of Vector DNA, 150 μg of puPA, 150 μg
of puPAR and 150 μg of pU2]. All experiments were
performed in compliance with institutional guidelines
established by the University Of Illinois College Of
Medicine at Peoria. After five weeks or when the control
mice started showing symptoms, mice were euthanized
by cardiac perfusion with formaldehyde. The brains
were then removed and paraffin embedded following
standard protocols. Sections were prepared with H&E.
In each case sections were blindly reviewed and scored
semi-quantitatively for tumor size. Sections were
observed and immunohistochemical analysis for Notch 1
was done on paraffin-embedded brain tumor sections of
mice treated with pSV, puPA and pU2 with specific
antibody for Notch 1.
Results and Discussion
Notch receptors are expressed in human glioblastoma
tissue microarray and in glioblastoma cells and glioma
xenograft cell lines
To determine if Notch is expressed in glioblastoma tis-
sues and cells, we wanted to check for Notch receptor
expression by GBM human tissue array, western blot and
by RT-PCR in U251 MG, 4910 and 5310 cells. Consistent
with previous reports, Notch 1, Notch 2, Notch 3 and
Notch 4 expression by immunohistochemistry was
observed in the GBM tissue array (Figure 1A, panels a, c,
e, and g ). Notch receptors 1 to 4 were minimally
expressed in normal brain tissue. (Figure 1A, panels b, d,
f, h) Further confirmation of our GBM tissue array
results was accomplished with immunofluorescent analy-
sis (data not shown). Lysates from all the three cell lines
showed expression of Notch 1, 2, 3, and 4 (Figure 1B)
and results of mRNA analysis by RT-PCR also showed
gene expression of all the four receptors (Figure 1C).
shRNA-mediated uPA/uPAR downregulation inhibits
anchorage independent growth of U251 MG, 5310 and
4910 cells
U251 MG, 5310, 4910 cells were left untransfected or
transfected with puPA, puPAR and pU2 were analyzed
by a colony formation assay in soft agar (Figure 1D).
puPA-, puPAR- and pU2-transfected U251 MG (Figure
1D, panel a to e), 5310 (Figure 1D, panel f to j) and
4910 (Figure 1D, panel k to o) cells showed significant
decreases in colony number (**p < 0.0001). Quantitative
analysis of the number of anchorage independent colo-
nies in soft agar after shRNA transfection in U251 MG,
5310 and 4910 cells is shown in Figure 1E. The colony
size was also decreased in the shRNA-transfected cells
in comparison to the controls. A complete recovery in
both colony number and size was obtained when exo-
genous uPA and ruPAR was added (data not shown)
indicating a specific role for uPA and uPAR in ancho-
rage-independent growth of U251, 5310 and 4910 cells.
To further confirm our results, we performed a matrigel
invasion assay in U251MG and 4910 cells left untrans-
fected or transfected with SV, puPA, puPAR and pU2
and with DAPT (an NICD inhibitor). Results showed
that invasion was inhibited in puPA, puPAR, pU2 and
DAPT-treated conditions compared with controls, sug-
gesting that inhibition of invasion by shRNA constructs
against uPA, uPAR and U2 is mediated by Notch-1
receptor (Figure 1F).
puPA, puPAR and pU2 inhibit cleavage of Notch receptor
in U251MG and xenograft cell lines
Notch receptor is cleaved by four enzymes and each
cleaved product is significant to its function. However,
cleavage of Notch 1 by gamma secretase is very critical
for the function of the Notch receptor. Cleavage of
Notch 1 by g secreatase results in the release of NICD
(Notch intracellular domain), and release of NICD to
the nucleus is critical for Notch gene expression. In all
of the three cell lines examined, we observed that
puPA, puPAR and pU2 inhibited the cleavage of the
Notch receptor as indicated by the absence of a
cleaved band at 80 Kda compared with the controls
(Figure 2A). Notch 1 is a transmembrane domain pro-
tein that is involved in the development and determi-
nation of cell fate [17]. During maturation, the Notch
Raghu et al. Molecular Cancer 2011, 10:130
http://www.molecular-cancer.com/content/10/1/130
Page 4 of 15
Figure 1 Expression of Notch signaling components in glioblastoma cancer cell line and xenograft cell lines. (A) Representative
composite of Notch 1, 2, 3 and 4 receptors by immunohistochemistry in glioblastoma human tissue array. (B) Western blot analysis of Notch
signaling components in three different cells, namely U251 MG and xenograft cell lines 5310 and 4910. (C) RT-PCR analysis of Notch 1, 2, 3 and 4
in U251 MG and xenograft cell lines, 5310 and 4910. (D) shRNA against uPA, uPAR and U2 inhibits anchorage independent growth of U251 MG
and glioblastoma xenograft cell lines in soft agar. (Panels a to e - U251 MG, panels f to j - 5310 and panels k to o - 4910). A total of 1 × 105 cells
from each cell line were left either untransfected or transfected with pSV, puPA, puPAR and pU2, and these cells were then plated in soft agar.
Representative photographs are shown which were taken at four weeks after the colonies were stained with crystal violet. (E) Quantitative
representation of number of anchorage-independent colonies in soft agar colony formation assay before and after transfection with pSV, puPA,
puPAR and pU2. Values are mean ± S.D. of three independent experiments, in comparison with controls (* P < 0.01, ** P < 0.001) (F) shRNA
against uPA, uPAR and U2 inhibits GBM invasion by a matrigel invasion assay as described previously in Material and Methods.
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Figure 2 Transcriptional inactivation of uPA and/or uPAR by shRNA inhibits cleavage of Notch 1 receptor, Notch 1 gene expression in
U251 MG, 4910 and 5310 xenograft cells. (A) Whole cell lysates were prepared from U251 MG, 4910 and 5310 cells which were left
untransfected, or transfected with pSV, puPA, puPAR and pU2 to evaluate the protein levels of activated Notch 1 and for Notch 1 cleavage at
the Val 1744 position. Blots were probed with GAPDH antibody to analyze for equal loading of proteins. (B) & (C) Quantitative analysis of relative
Notch 1 expression and cleaved Notch expression in U251 MG, 5310 and 4910 cells. (D) Immunofluorescence analysis of U251MG cells left
untransfected or transfected with pSV, puPA, puPAR and pU2 and stained for NICD (Notch intracellular domain) and images taken with Olympus
Fluoview microscope. (E) RT-PCR analysis of Notch 1 mRNA expression in (a) U251 MG, 5310 and 4910 cells which were left untransfected or
transfected with pSV, puPA, puPAR and pU2. GAPDH was used as an internal control. (F) Quantitative representation of Notch 1 mRNA levels in
U251MG, 5310 and 4910 cells. Values are mean ± S.D. of three independent experiments (* P < 0.01, **P < 0.001).
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molecule is cleaved by a furin-like convertase at its
extracellular domain [18]. Upon ligand binding, the
carboxy terminal Notch 1 fragment is released and is
further cleaved at Gly 1743 and Val 1744 [19,20].
Endogenous levels of cytosolic domain are observed
only upon cleavage between Gly 1743 and Val 1744.
Results show cleavage of Notch at the Val 1744 posi-
tion is inhibited in puPA- and pU2-transfected U251,
4910 and 5310 cells (Figure 2A). Quantitative repre-
sentation of activated Notch 1 and cleaved Notch 1
levels is shown in Figure 2B and Figure 2C, respec-
tively. To further confirm our western blotting results,
we checked for the NICD domain in U251 MG cells
by staining the cells with an antibody to NICD in
untreated U251 MG cells and in U251 MG cells trans-
fected with pSV, puPA, puPAR and pU2. As demon-
strated by our western blot results, we observed
increased expression of NICD in mock and pSV-trea-
ted cells (Figure 2D, panel a & b) while the cells trea-
ted with the three shRNA constructs showed very little
staining (Figure 2D, panel c to e). NICD staining was
seen as small green spots at the periphery and at the
center of the cells.
puPA, puPAR and pU2 inhibits the gene expression of
Notch 1 mRNA in all the three cell lines examined
To determine whether puPA, puPAR and pU2 inhibit
Notch 1 mRNA, we subjected controls and shRNA-
transfected U251 MG, 5310 and 4910 cells to RT PCR
for Notch 1 gene expression. Results showed that simul-
taneous down regulation of uPA and uPAR by pU2 effi-
ciently down regulated Notch 1 mRNA in all three cell
lines compared with puPA and puPAR (Figure 2E).
Quantitative analysis of the RT-PCR results is shown in
Figure 2F. These results suggest that simultaneous down
regulation of both uPA and uPAR with pU2 is a better
approach to knockdown Notch 1 mRNA than using sin-
gle shRNA constructs.
Notch inhibits uPA expression and activity in
glioblastoma cells and xenografts
To ascertain whether Notch plays a role in regulating
uPA activity and expression, we transfected U251 MG,
5310 and 4910 cells with scrambled vector siRNA and
siRNA to Notch 1 and checked for uPA activity by
fibrinogen zymography and uPA expression using wes-
tern blotting. In all three cell lines tested, results
showed that Notch siRNA downregulated uPA expres-
sion (Figure 3A) and uPA activity (Figure 3B). This
probably suggests that Notch and uPA regulate each
other through a positive feedback mechanism. Quanti-
tative expression of relative uPA expression and rela-
tive uPA activity is shown in Figures 3C and Figure
3D, respectively.
Exogenous addition of uPA and uPAR activate Notch 1 in
uPAR antisense and in U251 MG cells
Our previous results showed that shRNA against uPA
and uPAR inhibits Notch expression and cleavage (Fig-
ure 2A). We wanted to check if addition of exogenous
uPA and uPAR activates the Notch 1 receptor in uPAR
antisense cells and in U251 MG cells. Our results indi-
cate that upon exogenous addition of uPA and ruPAR,
individually and in combination, Notch 1 expression
was activated in uPAR antisense cells and in U251 MG
cells (Figure 3E). This probably suggests that uPA inde-
pendent of its role as a uPAR ligand can activate the
Notch 1 receptor in glioblastoma cells.
uPA activates Notch 1 receptor independent of Notch
ligands, Delta and Jagged
To further clarify the role of uPA as a ligand for Notch
1 in glioblastoma cells, we wanted to ascertain if uPA
activates Notch 1 in uPAR antisense cells in both the
presence and absence of Notch ligands, namely Delta
and Jagged. For this purpose, we used siDelta and
siJagged transfected uPAR antisense cells and stimulated
these cells with uPA. Surprisingly, we found that in
uPAR antisense cells, exogenous uPA activated Notch 1
and showed a further increase in fold activation in the
presence of siDelta and Jagged siRNA (Figure 3F). These
results suggest that Notch 1 can be activated by uPA by
independent of uPAR and Notch ligands, Delta and
Jagged. Quantitative expression of Notch 1 expression
from Figure 3E &3F is depicted in Figure 3G and Figure
3H, respectively. Overall, these results indicate that
Notch 1 and uPA regulate each other in glioblastoma
and GBM uPAR antisense cells.
puPA, puPAR and pU2 inhibits NICD and HES-induced
AKT, NF-B and ERK pathways in U251 MG and 4910 cells
Previously, we have shown that down regulation of uPA,
uPAR and pU2 in SNB19 cells leads to decreased phos-
phorylation of AKT and mTOR at the Ser 2448 posi-
tion, and ERK downstream of AKT. To further confirm
these results in the cells lines used in this study, we
checked for phosphorylation of AKT, ERK and mTOR
after transfection with shRNA against uPA/uPAR, singly
and in combination. As anticipated, we observed that
transfection with puPA-, puPAR- and pU2-transfected
cells significantly down regulated phosphorylation of
AKT, mTOR and ERK pathways in the three cell lines
used in this study. (Figure 4A-C). Previous studies have
shown that NF-B is a downstream target for ERK [21].
To confirm whether uPA/uPAR downregulation inhibits
NF-B, which is downstream to ERK, we checked the
nuclear activation of p50 (NF-B1), p52 (NF-B2) and
p65 (Rel A). As expected, we observed significant reduc-
tion in the nuclear activation of p50, p52 and p65 in all
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Figure 3 uPA positively regulates Notch in glioblastoma cells. (A) U251 MG, 5310 and 4910 cells were transfected with pSV (scrambled
Vector) or with siRNA against Notch 1 and analyzed for uPA and Notch 1 expression by western blotting. Blots were probed with GAPDH
antibody to analyze for equal loading of proteins. (B) Fibrin zymography of U251 MG, 5310 and 4910 cells transfected with pSV (scrambled
Vector) and siNotch 1 was performed to analyze for uPA activity. (C) & (D) Quantitative expression of relative uPA expression and uPA activity in
pSV and siNotch-transfected cells. (E) Exogenous addition of purified uPA activates Notch 1 receptor in uPAR antisense cells and in U251 MG
cells. Whole cell lysates prepared from uPAR antisense and U251 MG cells, which were treated with purified uPA (250 ng), ruPAR (50 ng) and in
combination, were checked for Notch 1 expression by Western blotting analysis. Blots were probed with GAPDH antibody to analyze for equal
loading of lysates. (F) Whole cell lysates prepared from uPAR antisense cells which were left untreated, treated with purified uPA, transfected
with shRNA against Delta and Jagged (Notch 1 ligands) with and without stimulation with purified uPA and probed for Notch 1, Delta and
Jagged by Western blotting. Blots were probed with GAPDH antibody to analyze for equal loading of lysates. (G) Quantitative analysis of relative
Notch 1 expression represented in (E) and (H) Quantitative analysis of relative Notch 1 expression represented in (F). Values are mean ± S.D. of
three independent experiments in comparison with the controls (* P < 0/01, **P < 0.001).
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Figure 4 puPA inhibits NICD and HES1-induced AKT, NF-B and ERK phosphorylation in glioblastoma cells. Down regulation of uPA/
uPAR inhibits AKT, NF-B, ERK and mTOR pathway in (A) U251 MG (B) 5310 and (C) 4910 cells. pSV: scrambled vector; puPA: shRNA against uPA;
puPAR: shRNA against uPAR and pU2: shRNA against both uPA and uPAR, DAPT-GSI (Gamma secretase inhibitor). puPA, puPAR and pU2 inhibits
nuclear activation of p52, p65 and p50 in (D) U251 MG (E) 5310 and (F) 4910 cells. Nuclear extracts prepared from U251 MG, 5310 and 4910 cells
which were left untransfected, transfected with pSV, puPA, puPAR, and pU2 and treated with DAPT and analyzed for nuclear activation of p52,
p50 and p65 subunits of NF-B using the Active Motif Transcription factor analysis kit following the manufacturer’s instructions. puPA inhibits
NICD and HES- induced AKT and ERK phosphorylation and NF- p65 in U251 MG and 4910 cells. Whole cell lysates from (G) U251 MG or from (H)
4910 xenograft cells over expressing NICD (Notch intracellular domain) or HES were transfected with pSV, transfected with puPA and were
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three cell lines tested (Figure 4D-F). Overall, these
results suggest that shRNA against uPA, uPAR and U2
inhibits AKT/mTOR, ERK and NF-B pathways in glio-
blastoma cells and xenografts.
The cross talk between Notch signaling and AKT/
mTOR pathways has been reported in the literature in
many studies [22-24]. Previous reports in the literature
[25,26] have shown that there is a cross talk between
Notch and NF-B. To determine whether puPA down
regulates Notch-induced AKT, NF-B and ERK pathways,
we overexpressed NICD and HES1 in U251 MG and 4910
cells. We also transfected these cells with puPA to check if
puPA inhibits NICD and HES-induced phosphorylation of
AKT, NF-B and phosphorylation of ERK. Interestingly,
we observed activation of AKT, ERK and NF-B in pSV-
transfected cells and in NICD and HES1-overexpressed
cells (Figure 4G and 4H). AKT, ERK phosphorylation and
NF-kB p65 levels were significantly down regulated upon
transfection with puPA (Figure 4G and 4H). To confirm
the cross talk of AKT/mTOR/NF- B/ERK pathways with
Notch-1, U251MG and 4910 cells were left untreated or
treated with pSV and siNotch 1 and checked for the
expression of pmTOR, pERK, pAKT and NF-kB p65.
Results showed that siNotch 1 inhibited phosphorylation
of AKT, ERK, mTOR and NF-kB levels compared with
controls in both the cell lines tested (Figure 4I and Figure
4J). To further confirm if NICD/HES1-overexpressed
Notch 1 is inhibited by puPA, puPAR and pU2 shRNA
constructs, we checked for Notch 1 expression in
U251MG and 4910 cells after transfection with shRNA
constructs against uPA, uPAR and U2. Results showed
that NICD/HES1 induced Notch1 expression levels were
significantly reduced in uPA andU2 transfected cells and
moderately in puPAR transfected cells (Figure 4K and Fig-
ure 4L). These results suggest that shRNA against uPA,
uPAR and U2 inhibit AKT, ERK and NF- B pathways.
These results also show that shRNA against uPA down
regulates NICD and HES-induced Notch1, AKT, NF-B
and ERK activation in glioblastoma cell lines.
Transcriptional inactivation of uPA/uPAR inhibits
trafficking of Notch 1 receptor in the U251 MG cell line
The trafficking of Notch receptor is known to be
mediated by endosomes. To determine if Notch 1 is
targeted to lysosomes after transfection with shRNA
against uPA, uPAR and U2 (bicistronic construct), we
conducted immunofluorescent staining in U251 cells
after transfection and checked for co-localization of
NICD with LAMP-1 (a lysosomal marker). We did not
observe co-localization of Notch 1 with LAMP-1 in
mock and pSV-treated cells (Figure 5A, panel a to f) but
there were few spots of co-localization in puPA- (Figure
5A, panel g to i) and puPAR- (Figure 5A, panel j to l)
treated cells. In pU2-treated cells, we were able to
observe a significant association of Notch 1 receptor
with LAMP-1, as indicated by a significant number of
yellow spots which is suggestive of co-localization (Fig-
ure 5A, panel m to o). The percent of cell count show-
ing co-localization is depicted quantitatively in Figure
5B. This result suggests that Notch 1 receptor trafficking
is significantly affected in puPA- puPAR- and pU2-
transfected U251 MG cells.
puPA and pU2 affect growth and pre-established
intracranial tumors in nude mice
To further confirm our in vitro results, we checked if
shRNA against puPA and pU2 affected pre-established
intracranial tumors in nude mice and also assessed
Notch 1 expression. In U251 MG pre-established intra-
cranial tumors, we observed expression of Notch 1 (Fig-
ure 6A, panel a to c), but in puPA-treated tumors, we
observed a significant decrease in the tumor margin and
infiltration, as well as in inhibition of Notch 1 expres-
sion (Figure 6A, panel d to f). In pU2-treated tumors,
the tumor margin showed more inhibition than in
puPA-treated tumors, and there was also significant
inhibition of Notch 1 expression and more inhibition at
the tumor margin than in puPA- treated tumors. (Figure
6A, panel g to i). Overall, these results show that uPA
and uPAR down regulation in combination inhibits
invasion in glioblastoma cells by down regulation of
Notch 1 receptor activation and expression, as well as
by blocking the trafficking of the Notch 1 receptor.
Expression of Notch 1 has been reported in various
types of human cancers [27,28]. Notch 1 has shown to
be involved in several functions in cancer cells including
proliferation, invasion and angiogenesis [21,29,30]. In
this study, we report that Notch 1 is over expressed in
immunoblotted for pAKT, NF-B p65 and pERK. Blots were reprobed with GAPDH to analyze for equal loading of proteins. Data represents
average of triplicates normalized to GAPDH (**p < 0.01). (I & J) siRNA against Notch 1 inhibits phosphorylated forms of mTOR/ERK/AKT and NF-
B p65 in (I) U251MG and (J) 4910 cells. Whole cell lysates from U251MG and 4910 cells were left untreated, transfected with pSV and siNotch
for 48 hrs and were immunoblotted for pmTOR, pERK, pAKT and NF- B p65. A representative blot of three independent experiments is shown.
Blots were reprobed with e GAPDH to analyze for equal loading of proteins. (K&L) shRNA against uPA, uPAR and U2 inhibited NICD/HES1
induced Notch 1 expression in U251MG and 4910 cells. (K) Whole cell lysates from (G) U251 MG or from (H) 4910 xenograft cells over expressing
NICD (Notch intracellular domain) or HES were transfected with pSV, puPA, puPAR and pU2 and were immunoblotted for Notch 1 expression. A
representative blot of three independent experiments is shown. Blots were reprobed with GAPDH to analyze for equal loading of proteins.
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glioblastoma cell line U251 MG and xenografts consis-
tent with previous studies [11,12,31]. Studies by us and
others have previously shown that simultaneous down
regulation of uPA and uPAR in glioblastoma cells signifi-
cantly down regulated invasion and angiogenesis by in
vitro and in vivo [32,33]. In this study, we found that
Notch 1 is a direct target for puPA and by pU2. Studies
by many groups [11,34,35] have shown that Notch 1 is
target for many genes in glioblastoma, and siRNA against
Notch 1 down regulates uPA and inhibits prostate cancer
and pancreatic cancer cell invasion [27,36]. Inspite of this
current knowledge, the role of uPA and uPAR down reg-
ulation in glioma cell invasion remains poorly under-
stood. In this study, we show that knockdown of uPA
and uPAR in tandem inhibits cleavage of the Notch
receptor, down regulates Notch 1 gene expression and
Notch 1 signaling cross talk, and significantly blocks the
trafficking of the Notch receptor in glioblastoma cells.
As previously shown in glioblastoma cell line SNB19,
we observed that targeted down regulation of uPA and
uPAR by single and bicistronic constructs inhibited
invasion in U251 MG and in glioma xenografts 4910
and 5310 by Matrigel invasion assay (Figure 1F) and
also anchorage independent growth by soft agar colony
formation assay (Figure 1D). Increased expression of
Notch 1 has been detected in brain tumors [37] and
other cancers [38,39]. The role of Notch 1 in different
cancers is considerably varied [40]. As previously
reported [11], we observed increased expression of
Notch 1 in glioma human tissue array, western blot and
RT-PCR.
The down regulation of uPA and uPAR inhibited acti-
vated Notch 1 activity and cleavage of Notch 1 at the
Val 1744 position which resulted in the inhibition of
Notch gene transcription. Moreover, glioblastoma cells
treated with siRNA against Notch showed decreased
Figure 5 puPA, puPAR and pU2 inhibits trafficking of Notch 1 receptor in U251 MG cells. (A) U251 MG cells left untreated (panels a to c)
or transfected with pSV (panels d to f), pupa (panels g to i), puPAR (panels j to l) and pU2 (panels m to o) were washed, fixed and
permeabilized, and then blocked with normal goat serum and incubated with primary antibodies against Notch 1 and LAMP-1 for 1 hr at RT.
The cells were then washed and incubated with Alexa fluor 488 and Alexa fluor 594 conjugated appropriate secondary antibodies. The cells
were then washed, and mounted with an anti-fade reagent and viewed under an Olympus fluoview fluorescent microscope. Arrows indicate
areas of co-localization. (B) Quantitative representation showing percentage cell count with co-localization of Notch 1 and LAMP1. Data
represents average of three independent experiments (**P < 0.01, *P < 0.05; in comparison with the controls).
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uPA expression as shown by western blotting and
decreased uPA activity by fibrin zymography. Based on
these observations, it is tempting to speculate that the
uPA/uPAR system might play a direct role in Notch 1
signaling and that uPA alone could directly regulate
Notch 1 in glioblastoma. Whether uPA/uPAR regulates
Notch 1 promoter activity is to be studied in future.
Our data corresponds to a previous study [41] which
showed that Notch 1 knockdown regulates the expres-
sion of uPA and uPAR by a distinct gene expression
mechanism in prostrate cancer cells. Bin Hafeez et al.
[41] conclude their study by stating that in addition to
MMP-9, uPA and uPAR might work synergistically to
enhance tumor invasion and metastasis in prostrate
Figure 6 puPA, puPAR and pU2 inhibits Notch 1 expression in pre established intracranial tumors in nude mice. (A) U251 MG cells in
suspension (2 × 106 in 10 μl serum-free medium) were injected by the intracranial route. One week later, the mice were injected with either
pSV or shRNA-expressing vectors (puPA and pU2) using an Alzet mini osmotic pump (constructs diluted to 1.5 μg ml-1 in PBS and injected at
0.25 μg hour-1, with six mice in each group). After a 5-week follow-up period, mice were sacrificed, their brains removed, paraffin embedded and
sectioned. Sections were observed and immunohistochemical analysis for Notch 1 was done on paraffin-embedded brain tumor sections of
mice treated with pSV, puPA and pU2 with specific antibody for Notch 1.
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cancer. As our results show that Notch 1 expression is
severely altered with puPA, puPAR and pU2 treatments,
we hypothesize that uPA/uPAR could be a target for
intervention in glioma.
Previous studies have shown that Notch 1 regulates
the PI3K/AKT/mTOR pathway in other cancers. Notch
1 has been reported to cross talk with the AKT pathway
in human cancer cells [22-24,42]. Studies by us have
also shown that uPA and uPAR down regulation inhibits
phosphorylation of Akt [32] in glioblastoma cells. Our
results suggest that inhibition of AKT/mTOR signaling
pathway via uPA/uPAR down regulation might be
mediated by Notch 1 signaling in glioblastoma cells.
Phosphorylation of AKT induced by NICD and HES 1
over expression was down regulated by shRNA against
uPA in GBM cells. These results suggest the existence
of a reciprocal regulation of Notch-1 and AKT pathway
in uPA/uPAR down regulation in glioblastoma cells.
Notch is known to cross talk with NF-B and ERK
pathways which are downstream of AKT [27,36]. Our
studies have shown that uPA/uPAR down regulation
inhibits nuclear activation of NF-B [43] and phosphor-
ylation of ERK [41]. The present study has also shown
that NF-B and AKT induced by NICD and HES1 over
expression in glioblastoma cell lines is inhibited by
shRNA against uPA. Further in-depth mechanistic stu-
dies are required to understand the role of uPA in regu-
lation of Notch 1-induced AKT, NF-B and ERK
pathways. Our results have comprehensively suggested
that uPA/uPAR down regulation results in the inhibition
of invasion of GBM cells by targeting the Notch 1
receptor signaling, cleavage, decreased Notch1 mRNA
transcription and trafficking. Purow et al [11] have
shown that Notch siRNA leads to increased cell death,
decreased proliferation and inhibition of cell cycle in
glioblastoma cells. Our results suggest that uPA/uPAR
down regulation might regulate Notch 1-mediated
events in glioblastoma. Interestingly, our results show
that uPA/uPAR down regulation resulted in Delta and
Jagged downregulation (data not shown). Studies by
Purow et al [11] have also shown that Notch ligands
could themselves have a potential for transformation
and play important roles in gliomagenesis. How shRNA
against uPA and uPAR regulates Delta and Jagged is
under further investigation. Our results also show that
in uPAR antisense cells and in U251 MG cells, uPA was
able to activate Notch 1 in the absence of Delta and
Jagged ligands. These results suggest that uPA by itself
could mediate uPAR independent functions such as
Notch 1 regulation in glioblastoma cell lines.
Our studies also indicate that uPA/uPAR down regu-
lation also results in the lysosomal targeting of the
Notch 1 receptor in U251 MG cells. The mechanistic
details of lysosomal targeting are yet to be explored.
Notch 1 expression was also inhibited in pupa- and
pU2-treated pre-established intracranial tumors in nude
mice. Involvement of uPA/uPAR in a plethora of cellu-
lar processes in glioma gives us the advantage of target-
ing this multifunctional system for therapeutic
intervention in patients with high grade glioma.
Conclusions
In summary, we have presented experimental evidence
that strongly suggests the role of Notch 1 in uPA/uPAR
down regulation in glioblastoma. shRNA against uPA
and uPAR inhibited Notch 1 cleavage, Notch gene tran-
scription and Notch 1-mediated AKT/ERK phosphoryla-
tion and NF-B subunits. From our results, we can
conclude that down regulation of uPA/uPAR, singly and
in tandem, could be an effective therapeutic approach
for inactivation of Notch-1 cleavage, signaling and traf-
ficking and to down regulate Notch-signaling-induced
NF-B, ERK and AKT pathways which are known to
play roles in growth, migration, invasion and angiogen-
esis of glioblastoma. Based on our results, we provide a
hypothetical pathway by which uPA/uPAR inhibits the
Notch 1 pathway which may be partly mediated by
AKT/NF-B and ERK pathways. Overall, our results
suggest that targeting uPA/uPAR may be advantageous
for future treatment of gliomas.
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